Formica Vincenzo, Tesauro Manfredi, Cardillo Carmine and Roselli Mario Pages 157-164 (8)
It acts mainly as catabolic enzyme for a number of circulating proteins involved in common pathological conditions such as diabetes and cardiovascular disease and may represent a target to modulate bioavailability of crucial substrates.
The aim of the present review is to summarize data regarding CD26-based pharmacological interventions. Four main subtopics were identified:1) CD26 as the target of pharmacological inhibitors to increase bioavailability of glucagon-like petide-1 (GLP-1) and hence to enhance GLP-1 glucose-lowering activity in diabetic patients; 2) role of CD26 in the physiology and pathology of the cardiovascular system; 3) the adverse prognostic value of CD26 expression on cancer cells; 4) CD26 down-regulation on lymphocytes as a mechanism of TGF-beta immunomodulation.
CD26, colorectal cancer, dipeptidyl peptidase 4, glucagon-like petide-1, stromal cell-derived factor-1.
Medical Oncology Unit, Internal Medicine Department, University Hospital 'Tor Vergata' , Viale Oxford, 81, 00133 Rome, Italy.